CU24301B1 - Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3) - Google Patents
Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3)Info
- Publication number
- CU24301B1 CU24301B1 CUP2015000097A CU20150097A CU24301B1 CU 24301 B1 CU24301 B1 CU 24301B1 CU P2015000097 A CUP2015000097 A CU P2015000097A CU 20150097 A CU20150097 A CU 20150097A CU 24301 B1 CU24301 B1 CU 24301B1
- Authority
- CU
- Cuba
- Prior art keywords
- type
- angptl3
- angiopoyetina
- polypeptide
- joint
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/17—Angiopoietin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775400P | 2013-03-08 | 2013-03-08 | |
| US201461938123P | 2014-02-10 | 2014-02-10 | |
| PCT/US2014/022102 WO2014138687A1 (en) | 2013-03-08 | 2014-03-07 | Peptides and compositions for treatment of joint damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20150097A7 CU20150097A7 (es) | 2016-05-30 |
| CU24301B1 true CU24301B1 (es) | 2017-12-08 |
Family
ID=50390286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2015000097A CU24301B1 (es) | 2013-03-08 | 2014-03-07 | Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3) |
Country Status (38)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010273570B2 (en) | 2009-07-14 | 2014-07-03 | Novartis Ag | Mesenchymal stem cell differentiation |
| US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
| JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
| US20190245180A1 (en) | 2016-10-24 | 2019-08-08 | Sumitomo Chemical Company, Limited | Separator and secondary battery including the separator |
| WO2018088813A2 (ko) * | 2016-11-09 | 2018-05-17 | 아이씨엠 주식회사 | Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물 |
| CN109963579A (zh) * | 2016-11-14 | 2019-07-02 | 诺华股份有限公司 | 用于治疗软骨损伤和关节炎的方法和组合物 |
| CN108530619B (zh) * | 2017-03-01 | 2020-12-08 | 北京大学第三医院 | 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| MA53388A (fr) | 2018-07-25 | 2021-06-02 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
| AR116566A1 (es) * | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| EP3993820A4 (en) * | 2019-07-04 | 2023-08-16 | Cadila Healthcare Limited | VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES |
| KR102577697B1 (ko) | 2019-11-13 | 2023-09-14 | 주식회사 나이벡 | 염증 및 상처 치료용 펩타이드 |
| JP7298496B2 (ja) | 2020-01-31 | 2023-06-27 | トヨタ自動車株式会社 | 車両 |
| JP2024519893A (ja) | 2021-05-24 | 2024-05-21 | ノバルティス アーゲー | 変形性関節症の治療方法 |
| TW202306970A (zh) | 2021-05-24 | 2023-02-16 | 瑞士商諾華公司 | 用於治療骨關節炎之方法 |
| CN113683681B (zh) * | 2021-09-15 | 2023-10-03 | 山西锦波生物医药股份有限公司 | 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途 |
| CN113683678B (zh) * | 2021-09-15 | 2023-11-24 | 山西锦波生物医药股份有限公司 | 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途 |
| CN118251594A (zh) | 2021-11-10 | 2024-06-25 | 诺华股份有限公司 | 用于确定angptl多肽的生物活性的方法 |
| CN114377202B (zh) * | 2021-12-16 | 2023-01-24 | 方向前 | 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| KR20240087877A (ko) * | 2022-12-09 | 2024-06-20 | (주)케어젠 | 연골 재생용 펩타이드 및 이의 용도 |
| WO2025169047A1 (en) | 2024-02-05 | 2025-08-14 | Novartis Ag | Improved production of angptl3 mimetics |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5288931A (en) | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| WO1999055869A1 (en) | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
| EP1078046A4 (en) | 1998-05-12 | 2005-05-11 | Human Genome Sciences Inc | 97 HUMAN SECRETED PROTEINS |
| AU4643699A (en) | 1998-06-24 | 2000-01-10 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
| EP1159419A1 (en) | 1999-03-08 | 2001-12-05 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| GB9912350D0 (en) | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| AU4011300A (en) | 1999-07-20 | 2001-02-05 | Genentech Inc. | Compositions and methods for the treatment of immune related diseases |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| JP4202128B2 (ja) | 2000-10-16 | 2008-12-24 | ジェネンテック・インコーポレーテッド | Ｗｉｓｐポリペプチドを用いる治療方法 |
| US20040249141A1 (en) | 2000-10-16 | 2004-12-09 | Audrey Goddard | Tie ligand homologues |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| US20030027751A1 (en) | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
| US7083970B2 (en) | 2001-04-19 | 2006-08-01 | The Scripps Research Institute | Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| FI117667B (fi) | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| JP5105696B2 (ja) | 2001-11-16 | 2012-12-26 | ジェネンテック， インコーポレイテッド | アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| NZ540490A (en) | 2002-09-09 | 2007-10-26 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanal conjugates with human growth hormone |
| ES2324608T3 (es) | 2002-10-16 | 2009-08-11 | The Scripps Research Institute | Incorporacion especifica de sitio de cetoaminoacidos en proteinas. |
| MXPA05003978A (es) | 2002-10-16 | 2005-06-22 | Scripps Research Inst | Sintesis de glicoproteinas. |
| WO2004094593A2 (en) | 2003-04-17 | 2004-11-04 | The Scripps Research Institute | Expanding the eukaryotic genetic code |
| US20060160175A1 (en) | 2003-07-07 | 2006-07-20 | The Scripps Research Institute | Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof |
| WO2005019415A2 (en) | 2003-07-07 | 2005-03-03 | The Scripps Research Institute | Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof |
| WO2005007624A2 (en) | 2003-07-07 | 2005-01-27 | The Scripps Research Institute | Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof |
| CA2580840A1 (en) | 2004-09-21 | 2006-03-30 | The Scripps Research Institute | In vivo incorporation of alkynyl amino acids into proteins in eubacteria |
| EP1807515A4 (en) | 2004-10-27 | 2008-06-18 | Scripps Research Inst | Orthogonal translation components for the in vivo incorporation of unnatural amino acids |
| AU2006223579A1 (en) | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| JP5139271B2 (ja) | 2005-05-24 | 2013-02-06 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | 培養した造血幹細胞を拡大しかつ分析する方法 |
| US7960141B2 (en) | 2006-03-09 | 2011-06-14 | The Scripps Research Institute | Systems for the expression of orthogonal translation components in eubacterial host cells |
| AU2007328871B2 (en) | 2006-12-06 | 2013-11-21 | Seikagaku Corporation | Pharmaceutical agent having long-lasting effect of treating arthritic disorders |
| PL2121751T3 (pl) | 2006-12-08 | 2017-07-31 | Lexicon Pharmaceuticals, Inc. | Przeciwciała monoklonalne przeciwko ANGPTL3 |
| EP2118150B1 (en) | 2007-02-14 | 2015-09-23 | Biocompatibles UK Limited | Derivatisation of biological molecules |
| JP2010525836A (ja) | 2007-05-04 | 2010-07-29 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ヒト造血幹細胞のｅｘｖｉｖｏ増殖 |
| AU2010273570B2 (en) * | 2009-07-14 | 2014-07-03 | Novartis Ag | Mesenchymal stem cell differentiation |
| EP2670847B1 (en) | 2011-02-03 | 2016-10-05 | XOMA Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| EP2864360B1 (en) | 2012-06-25 | 2017-09-06 | The Brigham and Women's Hospital, Inc. | Targeted therapeutics |
| US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
| JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
-
2014
- 2014-03-06 JO JOP/2014/0076A patent/JO3564B1/ar active
- 2014-03-06 UY UY0001035368A patent/UY35368A/es active IP Right Grant
- 2014-03-07 EP EP14713728.5A patent/EP2964250B1/en active Active
- 2014-03-07 TW TW103108047A patent/TWI634124B/zh active
- 2014-03-07 PT PT14713728T patent/PT2964250T/pt unknown
- 2014-03-07 EA EA201591661A patent/EA035158B1/ru not_active IP Right Cessation
- 2014-03-07 AU AU2014225348A patent/AU2014225348B2/en active Active
- 2014-03-07 CN CN201480012768.9A patent/CN105025917B/zh active Active
- 2014-03-07 NZ NZ711037A patent/NZ711037A/en unknown
- 2014-03-07 MX MX2015011963A patent/MX365157B/es active IP Right Grant
- 2014-03-07 WO PCT/US2014/022102 patent/WO2014138687A1/en not_active Ceased
- 2014-03-07 ES ES14713728.5T patent/ES2684349T3/es active Active
- 2014-03-07 BR BR122016021558-0A patent/BR122016021558B1/pt active IP Right Grant
- 2014-03-07 KR KR1020157027474A patent/KR102267341B1/ko active Active
- 2014-03-07 PE PE2015001873A patent/PE20151528A1/es active IP Right Grant
- 2014-03-07 SG SG11201506490TA patent/SG11201506490TA/en unknown
- 2014-03-07 CU CUP2015000097A patent/CU24301B1/xx unknown
- 2014-03-07 CR CR20200290A patent/CR20200290A/es unknown
- 2014-03-07 HR HRP20181269TT patent/HRP20181269T1/hr unknown
- 2014-03-07 BR BR112015021269-7A patent/BR112015021269B1/pt active IP Right Grant
- 2014-03-07 DK DK14713728.5T patent/DK2964250T3/da active
- 2014-03-07 PL PL14713728T patent/PL2964250T3/pl unknown
- 2014-03-07 LT LTEP14713728.5T patent/LT2964250T/lt unknown
- 2014-03-07 MY MYPI2015702657A patent/MY173172A/en unknown
- 2014-03-07 CN CN202010722284.0A patent/CN111808182A/zh active Pending
- 2014-03-07 HU HUE14713728A patent/HUE038499T2/hu unknown
- 2014-03-07 AP AP2015008675A patent/AP2015008675A0/xx unknown
- 2014-03-07 CA CA2903448A patent/CA2903448C/en active Active
- 2014-03-07 EP EP18170788.6A patent/EP3391900A1/en active Pending
- 2014-03-07 SI SI201430757T patent/SI2964250T1/sl unknown
- 2014-03-07 RS RS20180794A patent/RS57446B1/sr unknown
- 2014-03-07 JP JP2015561740A patent/JP6567429B2/ja active Active
- 2014-03-07 US US14/772,209 patent/US9649359B2/en active Active
-
2015
- 2015-08-18 ZA ZA2015/05966A patent/ZA201505966B/en unknown
- 2015-08-20 IL IL240727A patent/IL240727B/en active IP Right Grant
- 2015-08-31 CL CL2015002443A patent/CL2015002443A1/es unknown
- 2015-09-03 TN TN2015000385A patent/TN2015000385A1/en unknown
- 2015-09-07 PH PH12015501983A patent/PH12015501983B1/en unknown
- 2015-09-08 CR CR20150466A patent/CR20150466A/es unknown
- 2015-09-08 CO CO15210900A patent/CO7461145A2/es unknown
- 2015-10-08 EC ECIEPI201542898A patent/ECSP15042898A/es unknown
-
2016
- 2016-05-11 AU AU2016203028A patent/AU2016203028C1/en active Active
- 2016-12-21 AU AU2016277608A patent/AU2016277608B2/en active Active
-
2017
- 2017-03-13 US US15/457,656 patent/US10328126B2/en active Active
-
2018
- 2018-08-07 CY CY181100821T patent/CY1120729T1/el unknown
-
2019
- 2019-05-06 US US16/403,677 patent/US11179442B2/en active Active
- 2019-07-30 JP JP2019140222A patent/JP6918871B2/ja active Active
-
2021
- 2021-07-20 JP JP2021119517A patent/JP2021178841A/ja active Pending
- 2021-11-08 US US17/453,960 patent/US20220184182A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24301B1 (es) | Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3) | |
| UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| CO7151525A2 (es) | Proteínas del factor 21 de crecimiento del fibroblasto | |
| GB202006164D0 (en) | Recombinant collagen and eslastin molecules and uses thereof | |
| MX383887B (es) | Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich. | |
| CR20160049A (es) | Bioconjugados de polipéptidos de apelina sintética | |
| DK3538559T3 (da) | Rekombinante pmhc klasse ii-molekyler | |
| CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
| BR112018007453A2 (pt) | genes modificados de ataxia de friedreich e vetores para a terapia gênica | |
| MX376324B (es) | Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos. | |
| PL3744731T3 (pl) | Białka fuzyjne FGF21 o przedłużonym działaniu i kompozycja farmaceutyczna je zawierająca | |
| BR112016018288A2 (pt) | proteínas de fusão de interleucina 2 e uso das mesmas | |
| MX384628B (es) | Polipéptidos que tienen actividad de transgalactosilación. | |
| CR20180292A (es) | Productos de contrucción que comprenden grafeno u óxido de grafeno en el material granel y procedimiento para la producción de tales productos de construcción | |
| DK3619324T3 (da) | Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf | |
| BR112017011226A2 (pt) | peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica | |
| CL2020000733A1 (es) | Proteína de fusión que comprende una porción de fgf-18. | |
| ES2663096T3 (es) | Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas | |
| IL262356A (en) | Polyethylene glycol-converted bioactive peptides and their uses | |
| BR112014016254A2 (pt) | proteína aglutina recombinante da folha de allium fistulosum, seu polinucleotídeo codificante, iniciador e processo para preparação da mesm | |
| DK3630793T3 (da) | Rekombinant protein | |
| BR112019005959A2 (pt) | gene dgkk recombinante para terapia genética da síndrome do x frágil | |
| EP3556370A4 (en) | OPHTHALMIC COMPOSITION CONTAINING SULFASALAZINE AND HYALURONIC ACID |